| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 83.30 | 14.4% | 81.6% |
| Total Income | 83.30 | 14.4% | 81.6% |
| Expenditure | 125.19 | 11.0% | 21.2% |
| PBT | — | ||
| Net Profit | -49.43 | 0.1% | 18.6% |
| OPM | -50.30% | 4.65pp | |
| NPM | -59.34% | 8.47pp | |
| EPS | -0.55 | 0.0% | 21.4% |
Syndax Pharmaceuticals Reports Q3 2026 Financial Results and Provides Business Update
03 Nov 2026 · 3 Nov, 2:37 am
Summary
Syndax Pharmaceuticals reported strong third quarter 2026 financial results, with total revenue reaching $83.3 million, an 82% increase year-over-year. This growth was driven by Revuforj net revenue of $60.7 million (up 90% YoY) and Niktimvo collaboration revenue of $22.6 million (up 63% YoY). The company reported a net loss of $49.4 million for the quarter. Management expressed confidence in the company's commercial performance and pipeline, highlighting upcoming data readouts and the potential for significant value creation.
Key Highlights
- 1
Total revenue for the third quarter of 2026 was $83.3 million, an 82% year-over-year increase.
- 2
Revuforj net revenue reached $60.7 million in 3Q26, marking a 90% year-over-year increase and a 11% quarter-over-quarter growth.
- 3
Niktimvo net revenue was $67.4 million in 3Q26, a 47% year-over-year increase, contributing $22.6 million in collaboration revenue to Syndax.
- 4
The company reported a net loss attributable to common stockholders of $49.4 million, or $0.55 per share, for the three months ended September 30, 2026.
- 5
Syndax expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and initiate a Phase 1 trial in 2027.
- 6
New Revuforj data is expected in 4Q26 from clinical trials and real-world studies, with a major presence planned at ASH.
- 7
Syndax ended the quarter with $551.1 million in cash, cash equivalents, and short- and long-term investments.
Management Comments
Michael A. Metzger
We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting. We continue to have the dominant share of new patients across all age groups starting a menin inhibitor and the vast majority of revenue for the class, underscoring our position as the market leader. Importantly, a growing number of both R/R KMT2Ar and NPM1m patients are proceeding to a stem cell transplant after receiving Revuforj and then resuming therapy afterward, a dynamic that positions the business for long-term growth as the average duration of therapy extends. We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity. With growing revenue from two medicines, a robust pipeline generating multiple blockbuster opportunities, world-class R&D capabilities, and a strong balance sheet, Syndax is poised to deliver long-term value.
Informational and educational content only. Not investment advice.